Premium
IL‐10 produced by activated human B cells regulates CD4 + T‐cell activation in vitro
Author(s) -
Bouaziz JeanDavid,
Calbo Sebastien,
MahoVaillant Maud,
Saussine Anne,
Bagot Martine,
Bensussan Armand,
Musette Philippe
Publication year - 2010
Publication title -
european journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.272
H-Index - 201
eISSN - 1521-4141
pISSN - 0014-2980
DOI - 10.1002/eji.201040673
Subject(s) - biology , cd38 , il 2 receptor , naive b cell , microbiology and biotechnology , interleukin 10 , b cell , stimulation , in vitro , downregulation and upregulation , t cell , immune system , b 1 cell , immunology , antigen presenting cell , stem cell , antibody , endocrinology , cd34 , biochemistry , gene
Abstract IL‐10‐producing regulatory B cells have been identified in mice and shown to downregulate inflammation, making them potentially important for maintenance of tolerance. In this study, we isolated B cells from human blood and spleen, and showed that after a short period of ex vivo stimulation a number of these cells produced IL‐10. The IL‐10‐producing B cells did not fall within a single clearly defined subpopulation, but were enriched in both the memory (CD27 + ) and the transitional (CD38 high ) B‐cell compartments. Combined CpG‐B+anti‐Ig stimulation was the most potent IL‐10 stimulus tested. B cells stimulated in this way inhibited CD4 + CD25 − T‐cell proliferation in vitro by a partially IL‐10‐dependent mechanism. These findings imply that manipulating IL‐10 production by human B cells could be a useful therapeutic strategy for modulating immune responses in humans.